Pruritus in cholestatic liver diseases can be a major burden and dramatically impair the quality of life of those affected. Here, we provide an update on the latest insights into the molecular pathogenesis of and novel therapeutic approaches for cholestasis-associated itch. Endogenous and exogenous small-molecule pruritogen candidates bind to their receptors on unmyelinated itch C-fibres in the skin. Candidate pruritogens in cholestasis include certain lysophospholipids and sulfated progesterone metabolites, among others, whereas total bile acid or bilirubin conjugates seem unlikely to have a dominant role in the pathogenesis of cholestasis-associated pruritus. Transmission of itch signals via primary, secondary and tertiary itch neurons to the postcentral gyrus and activation of scratch responses offer various targets for therapeutic intervention. At present, evidence-based treatment options for pruritus in fibrosing cholangiopathies, such as primary biliary cholangitis and primary sclerosing cholangitis, are the peroxisome proliferator-associated receptor (PPAR) agonist bezafibrate and the pregnane X receptor (PXR) agonist rifampicin. In pruritus of intrahepatic cholestasis of pregnancy, ursodeoxycholic acid is recommended and might be supported in the third trimester by rifampicin if needed. Alternatively, non-absorbable anion exchange resins, such as cholestyramine, can be administered, albeit with poor trial evidence. Liver transplantation for intolerable refractory pruritus has become an extremely rare therapeutic strategy.
Pruritus can be a burdensome symptom, dramatically impairing the quality of life of people affected with a cholestatic liver disease.
Potential pruritogens in cholestasis activate a complex neural network leading to the sensation of itch.
Candidate pruritogens include certain lysophospholipids and sulfated progesterone metabolites, among others.
First-line effective treatment options for pruritus in fibrosing cholangiopathies, such as primary biliary cholangitis and primary sclerosing cholangitis, are the peroxisome proliferator-associated receptor (PPAR) agonist bezafibrate and the pregnane X receptor (PXR) agonist rifampicin.
First-line treatment in intrahepatic cholestasis of pregnancy remains ursodeoxycholic acid, supported in the third trimester by rifampicin, if needed.
This is a preview of subscription content, access via your institution
Subscribe to Nature+
Get immediate online access to Nature and 55 other Nature journal
Subscribe to Journal
Get full journal access for 1 year
only $6.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Alighieri, D. La Divina Commedia - I. Inferno Canto XXIX (1307–1321).
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J. Hepatol. 51, 237–267 (2009).
Kremer, A. E., Beuers, U., Oude-Elferink, R. P. & Pusl, T. Pathogenesis and treatment of pruritus in cholestasis. Drugs 68, 2163–2182 (2008).
Bergasa, N. V. The itch of liver disease. Semin. Cutan. Med. Surg. 30, 93–98 (2011).
Beuers, U., Kremer, A. E., Bolier, R. & Elferink, R. P. Pruritus in cholestasis: facts and fiction. Hepatology 60, 399–407 (2014).
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis. J. Hepatol. 67, 145–172 (2017).
Mayo, M. J. et al. Impact of pruritus on quality of life and current treatment patterns in patients with primary biliary cholangitis. Dig. Dis. Sci. https://doi.org/10.1007/s10620-022-07581-x (2022).
van Munster, K. N., Dijkgraaf, M. G. W., Oude Elferink, R. P. J., Beuers, U. & Ponsioen, C. Y. Symptom patterns in the daily life of PSC patients. Liver Int. 42, 1562–1570 (2022).
Kenyon, A. P. et al. Pruritus in pregnancy: a study of anatomical distribution and prevalence in relation to the development of obstetric cholestasis. Obstet. Med. 3, 25–29 (2010).
McPhedran, N. T. & Henderson, R. D. Pruritus and Jaundice. Can. Med. Assoc. J. 92, 1258–1260 (1965).
Loomba, R. et al. Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis attributable to NASH. Hepatology 73, 625–643 (2021).
Langedijk, J., Beuers, U. H. & Oude Elferink, R. P. J. Cholestasis-associated pruritus and its pruritogens. Front. Med. 8, 639674 (2021).
Kremer, A. E., Feramisco, J., Reeh, P. W., Beuers, U. & Oude Elferink, R. P. Receptors, cells and circuits involved in pruritus of systemic disorders. Biochim. Biophys. Acta 1842, 869–892 (2014).
Perino, A., Demagny, H., Velazquez-Villegas, L. & Schoonjans, K. Molecular physiology of bile acid signaling in health, disease, and aging. Physiol. Rev. 101, 683–731 (2021).
Fiorucci, S. & Distrutti, E. The pharmacology of bile acids and their receptors. Handb. Exp. Pharmacol. 256, 3–18 (2019).
Kremer, A. E. et al. Lysophosphatidic acid is a potential mediator of cholestatic pruritus. Gastroenterology 139, 1008–1018 (2010).
Ghent, C. N., Bloomer, J. R. & Klatskin, G. Elevations in skin tissue levels of bile acids in human cholestasis: relation to serum levels and topruritus. Gastroenterology 73, 1125–1130 (1977).
Alemi, F. et al. The TGR5 receptor mediates bile acid-induced itch and analgesia. J. Clin. Invest. 123, 1513–1530 (2013).
Yu, H. et al. MRGPRX4 is a bile acid receptor for human cholestatic itch. eLife 8, e48431 (2019).
de Vries, E. et al. Fibrates for Itch (FITCH) in fibrosing cholangiopathies: a double-blind, randomized, Placebo-controlled trial. Gastroenterology 160, 734–743 (2021).
Beuers, U. et al. Effect of ursodeoxycholic acid on the kinetics of the major hydrophobic bile acids in health and in chronic cholestatic liver disease. Hepatology 15, 603–608 (1992).
Cole, S. P. et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258, 1650–1654 (1992).
Meixiong, J., Vasavda, C., Snyder, S. H. & Dong, X. MRGPRX4 is a G protein-coupled receptor activated by bile acids that may contribute to cholestatic pruritus. Proc. Natl Acad. Sci. USA 116, 10525–10530 (2019).
Harms, M. H. et al. Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis. J. Hepatol. 71, 357–365 (2019).
Hempfling, W., Dilger, K. & Beuers, U. Systematic review: ursodeoxycholic acid — adverse effects and drug interactions. Aliment. Pharmacol. Ther. 18, 963–972 (2003).
Dilger, K. et al. Effect of ursodeoxycholic acid on bile acid profiles and intestinal detoxification machinery in primary biliary cirrhosis and health. J. Hepatol. 57, 133–140 (2012).
Langedijk, J. et al. Reduced spontaneous itch in mouse models of cholestasis. Sci. Rep. 11, 6127 (2021).
Cipriani, S. et al. Impaired itching perception in murine models of cholestasis is supported by dysregulation of GPBAR1 signaling. PLoS ONE 10, e0129866 (2015).
Lieu, T. et al. The bile acid receptor TGR5 activates the TRPA1 channel to induce itch in mice. Gastroenterology 147, 1417–1428 (2014).
Ostadhadi, S. et al. Evidence for the involvement of nitric oxide in cholestasis-induced itch associated response in mice. Biomed. Pharmacother. 84, 1367–1374 (2016).
Boyer, J. L. Bile formation and secretion. Compr. Physiol. 3, 1035–1078 (2013).
Nevens, F. et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N. Engl. J. Med. 375, 631–643 (2016).
Shah, R. A. & Kowdley, K. V. Obeticholic acid for the treatment of nonalcoholic steatohepatitis. Expert Rev. Gastroenterol. Hepatol. 14, 311–321 (2020).
Neuschwander-Tetri, B. A. et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385, 956–965 (2015).
Fiorucci, S. et al. Targeting FXR in cholestasis: hype or hope. Expert Opin. Ther. Targets 18, 1449–1459 (2014).
Trauner, M. et al. The nonsteroidal farnesoid X receptor agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis. Hepatology 70, 788–801 (2019).
Gege, C., Hambruch, E., Hambruch, N., Kinzel, O. & Kremoser, C. Nonsteroidal FXR ligands: current status and clinical applications. Handb. Exp. Pharmacol. 256, 167–205 (2019).
Kremoser, C. FXR agonists for NASH: How are they different and what difference do they make? J. Hepatol. 75, 12–15 (2021).
Erken, R. et al. Farnesoid X receptor agonist for the treatment of chronic hepatitis B: a safety study. J. Viral Hepat. https://doi.org/10.1111/jvh.13608 (2021).
Kuiper, E. M. et al. The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial. Hepatology 52, 1334–1340 (2010).
Vaz, F. M. et al. Sodium taurocholate cotransporting polypeptide (SLC10A1) deficiency: conjugated hypercholanemia without a clear clinical phenotype. Hepatology 61, 260–267 (2015).
Van Herpe, F. et al. NTCP deficiency and persistently raised bile salts: an adult case. J. Inherit. Metab. Dis. 40, 313–315 (2017).
Dong, C. et al. Clinical and histopathologic features of sodium taurocholate cotransporting polypeptide deficiency in pediatric patients. Medicine 98, e17305 (2019).
Zou, T. T., Zhu, Y., Wan, C. M. & Liao, Q. Clinical features of sodium-taurocholate cotransporting polypeptide deficiency in pediatric patients: case series and literature review. Transl. Pediatr. 10, 1045–1054 (2021).
Erlinger, S. NTCP deficiency: a new inherited disease of bile acid transport. Clin. Res. Hepatol. Gastroenterol. 39, 7–8 (2015).
Meixiong, J. et al. Identification of a bilirubin receptor that may mediate a component of cholestatic itch. eLlife https://doi.org/10.7554/eLife.44116 (2019).
Stapelbroek, J. M., van Erpecum, K. J., Klomp, L. W. & Houwen, R. H. Liver disease associated with canalicular transport defects: current and future therapies. J. Hepatol. 52, 258–271 (2010).
Aronson, S. J. et al. Disease burden and management of Crigler-Najjar syndrome: report of a world registry. Liver Int. 42, 1593–1604 (2022).
Reyes, H. & Sjovall, J. Bile acids and progesterone metabolites in intrahepatic cholestasis of pregnancy. Ann. Med. 32, 94–106 (2000).
Reyes, H. Sulfated progesterone metabolites in the pathogenesis of intrahepatic cholestasis of pregnancy: another loop in the ascending spiral of medical knowledge. Hepatology 63, 1080–1082 (2016).
Parizek, A. et al. A comprehensive evaluation of steroid metabolism in women with intrahepatic cholestasis of pregnancy. PLoS ONE 11, e0159203 (2016).
Abu-Hayyeh, S. et al. Prognostic and mechanistic potential of progesterone sulfates in intrahepatic cholestasis of pregnancy and pruritus gravidarum. Hepatology https://doi.org/10.1002/hep.28265 (2016).
Hashimoto, T., Ohata, H. & Momose, K. Itch-scratch responses induced by lysophosphatidic acid in mice. Pharmacology 72, 51–56 (2004).
van Meeteren, L. A. et al. Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol. Cell Biol. 26, 5015–5022 (2006).
Kremer, A. E. et al. Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions. Hepatology 56, 1391–1400 (2012).
Langedijk, J. et al. Inhibition of autotaxin by bile salts and bile salt-like molecules increases its expression by feedback regulation. Biochim. Biophys. Acta Mol. Basis Dis. 1867, 166239 (2021).
Keune, W. J. et al. Steroid binding to Autotaxin links bile salts and lysophosphatidic acid signalling. Nat. Commun. 7, 11248 (2016).
Benesch, M. G., Zhao, Y. Y., Curtis, J. M., McMullen, T. P. & Brindley, D. N. Regulation of autotaxin expression and secretion by lysophosphatidate and sphingosine 1-phosphate. J. Lipid Res. 56, 1134–1144 (2015).
Kremer, A. E. et al. Autotaxin activity has a high accuracy to diagnose intrahepatic cholestasis of pregnancy. J. Hepatol. 62, 897–904 (2015).
Chen, Y. et al. Transient receptor potential vanilloid 4 ion channel functions as a pruriceptor in epidermal keratinocytes to evoke histaminergic itch. J. Biol. Chem. 291, 10252–10262 (2016).
Chen, Y. et al. Epithelia-sensory neuron cross talk underlies cholestatic itch induced by lysophosphatidylcholine. Gastroenterology 161, 301–317 (2021).
Li, X. et al. MicroRNA-146a is linked to pain-related pathophysiology of osteoarthritis. Gene 480, 34–41 (2011).
Han, Q. et al. miRNA-711 binds and activates TRPA1 extracellularly to evoke acute and chronic pruritus. Neuron 99, 449–463.e6 (2018).
Park, C. K. et al. Extracellular microRNAs activate nociceptor neurons to elicit pain via TLR7 and TRPA1. Neuron 82, 47–54 (2014).
European Association for the Study of the Liver. EASL Clinical Practice Guidelines on sclerosing cholangitis.J. Hepatol. 77, 761–806 (2022).
Palma, J. et al. Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo. J. Hepatol. 27, 1022–1028 (1997).
Glantz, A., Marschall, H. U., Lammert, F. & Mattsson, L. A. Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. Hepatology 42, 1399–1405 (2005).
Kondrackiene, J., Beuers, U. & Kupcinskas, L. Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy. Gastroenterology 129, 894–901 (2005).
Bacq, Y. et al. Efficacy of ursodeoxycholic acid in treating intrahepatic cholestasis of pregnancy: a meta-analysis. Gastroenterology 143, 1492–1501 (2012).
Gurung, V., Middleton, P., Milan, S. J., Hague, W. & Thornton, J. G. Interventions for treating cholestasis in pregnancy. Cochrane Database Syst. Rev. https://doi.org/10.1002/14651858.CD000493.pub2 (2013).
Beuers, U., Trauner, M., Jansen, P. & Poupon, R. New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond. J. Hepatol. 62 (Suppl. 1), 25–37 (2015).
Beuers, U. Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat. Clin. Pract. Gastroenterol. Hepatol. 3, 318–328 (2006).
Chappell, L. C. et al. Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial. Lancet 394, 849–860 (2019).
Chappell, L. C. et al. Ursodeoxycholic acid versus placebo, and early term delivery versus expectant management, in women with intrahepatic cholestasis of pregnancy: semifactorial randomised clinical trial. BMJ 344, e3799 (2012).
Beuers, U. & de Vries, E. Reply to: “UDCA therapy in intrahepatic cholestasis of pregnancy?”. J. Hepatol. 72, 587–588 (2020).
Mitchell, A. L. et al. Re-evaluating diagnostic thresholds for intrahepatic cholestasis of pregnancy: case-control and cohort study. BJOG 128, 1635–1644 (2021).
de Vries, E. & Beuers, U. Ursodeoxycholic acid in pregnancy? J. Hepatol. 71, 1237–1245 (2019).
Ovadia, C. et al. Ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: a systematic review and individual participant data meta-analysis. Lancet Gastroenterol. Hepatol. 6, 547–558 (2021).
Geenes, V. et al. Rifampicin in the treatment of severe intrahepatic cholestasis of pregnancy. Eur. J. Obstet. Gynecol. Reprod. Biol. 189, 59–63 (2015).
Hague, W. M. et al. A multi-centre, open label, randomised, parallel-group, superiority Trial to compare the efficacy of URsodeoxycholic acid with RIFampicin in the management of women with severe early onset Intrahepatic Cholestasis of pregnancy: the TURRIFIC randomised trial. BMC Pregnancy Childbirth 21, 51 (2021).
Rust, C. et al. Effect of cholestyramine on bile acid pattern and synthesis during administration of ursodeoxycholic acid in man. Eur. J. Clin. Invest. 30, 135–139 (2000).
European Association for the Study of the Liver. EASL clinical practice guidelines on sclerosing cholangitis. J. Hepatol. https://doi.org/10.1016/j.jhep.2022.05.011 (2022).
Lindor, K. D. et al. Primary biliary cirrhosis. Hepatology 50, 291–308 (2009).
Agrawal, R. et al. Effectiveness of bezafibrate and ursodeoxycholic acid in patients with primary biliary cholangitis: a meta-analysis of randomized controlled trials. Ann. Gastroenterol. 32, 489–497 (2019).
Lens, S., Leoz, M., Nazal, L., Bruguera, M. & Pares, A. Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid. Liver Int. 34, 197–203 (2014).
Reig, A., Sese, P. & Pares, A. Effects of bezafibrate on outcome and pruritus in primary biliary cholangitis with suboptimal ursodeoxycholic acid response. Am. J. Gastroenterol. 113, 49–55 (2018).
Corpechot, C. et al. A placebo-controlled trial of bezafibrate in primary biliary cholangitis. N. Engl. J. Med. 378, 2171–2181 (2018).
Hegade, V. S., Jones, D. E. & Hirschfield, G. M. Apical sodium-dependent transporter inhibitors in primary biliary cholangitis and primary sclerosing cholangitis. Dig. Dis. 35, 267–274 (2017).
Hegade, V. S. et al. Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study. Lancet 389, 1114–1123 (2017).
Al-Dury, S. et al. Pilot study with IBAT inhibitor A4250 for the treatment of cholestatic pruritus in primary biliary cholangitis. Sci. Rep. 8, 6658 (2018).
Kamath, B. M., Stein, P., Houwen, R. H. J. & Verkade, H. J. Potential of ileal bile acid transporter inhibition as a therapeutic target in Alagille syndrome and progressive familial intrahepatic cholestasis. Liver Int. 40, 1812–1822 (2020).
Gonzales, E. et al. Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study. Lancet 398, 1581–1592 (2021).
Baumann, U. et al. Effects of odevixibat on pruritus and bile acids in children with cholestatic liver disease: phase 2 study. Clin. Res. Hepatol. Gastroenterol. 45, 101751 (2021).
Kumada, H. et al. Efficacy of nalfurafine hydrochloride in patients with chronic liver disease with refractory pruritus: a randomized, double-blind trial. Hepatol. Res. 47, 972–982 (2017).
Golpanian, R. S., Yosipovitch, G. & Levy, C. Use of butorphanol as treatment for cholestatic itch. Dig. Dis. Sci. 66, 1693–1699 (2021).
Hegade, V. S. et al. The safety and efficacy of nasobiliary drainage in the treatment of refractory cholestatic pruritus: a multicentre European study. Aliment. Pharmacol. Ther. 43, 294–302 (2016).
The authors are grateful for stimulating discussions with Hanns-Ulrich Marschall, University of Gothenburg, Sweden, and Catherine Williamson, King’s College London, UK.
The authors declare no competing interests.
Peer review information
Nature Reviews Gastroenterology & Hepatology thanks Olivier Chazouilleres, Gil Yosipovitch and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Beuers, U., Wolters, F. & Oude Elferink, R.P.J. Mechanisms of pruritus in cholestasis: understanding and treating the itch. Nat Rev Gastroenterol Hepatol 20, 26–36 (2023). https://doi.org/10.1038/s41575-022-00687-7